https://orcid.org/0000-0002-0475-1093
Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Min Seok Kim, Jasmine Choi, Hyeong Du Lee & Se Joon Woo. (2021) Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Following Retinal Vein Occlusion: Post Hoc Analysis of Post-Marketing Surveillance Data in the Real-World Setting in Korea. Clinical Ophthalmology 15, pages 3623-3636.
Read now
Read now
Yong Luo, Jianbo Wan, Chang Luo, HengWei Liu, YuFan Zhou, Juan Chen, Yiqin Duan, Xiangyan Ning, Zengchao Zhou, Kehua Wang, Jun Li, Heping Xu & ZhongPing Chen. (2021) Higher Aqueous Levels of Resistin and Lipocalin-2 Indicated Worse Visual Improvement following anti-VEGF Therapy in Patients with Retinal Vein Occlusion. Current Eye Research 46:6, pages 845-854.
Read now
Read now
Faye Horner, Peck Lin Lip, Bushra Mushtaq, Randhir Chavan, Bashar Mohammed & Arijit Mitra. (2020) Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice. Clinical Ophthalmology 14, pages 955-965.
Read now
Read now
Articles from other publishers (17)
Lars-Olof Hattenbach, Francis Abreu, Pablo Arrisi, Karen Basu, Carl J. Danzig, Robyn Guymer, Zdenka Haskova, Jeffrey S. Heier, Aachal Kotecha, Ying Liu, Anat Loewenstein, András Seres, Jeffrey R. Willis, Charles C. Wykoff & Liliana P. Paris. (2023) BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion. Ophthalmology Science 3:3, pages 100302.
Crossref
Crossref
Yasha S. Modi, Lediana Goduni, Hadi Moini, Andrea Gibson, Nick Boucher, Genevieve Lucas & Dilsher S. Dhoot. (2023) Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion. Eye.
Crossref
Crossref
Jessica C. Liu, Peter Alsaloum, Amogh I. Iyer, Peter M. Kaiser & Rishi P. Singh. (2022) Consequences of anti-vascular endothelial growth factor treatment lapse in patients with retinal vein occlusion. Eye 37:3, pages 453-458.
Crossref
Crossref
Mads Odgaard Mæng, Nirrooja Roshanth, Anders Kruse, Jonas Ellegaard Nielsen, Benedict Kjærgaard, Bent Honoré, Henrik Vorum & Lasse Jørgensen Cehofski. (2023) Laser-Induced Porcine Model of Experimental Retinal Vein Occlusion: An Optimized Reproducible Approach. Medicina 59:2, pages 243.
Crossref
Crossref
Frank G Holz, Rodrigo Abreu-Gonzalez, Francesco Bandello, Renaud Duval, Louise O'Toole, Daniel Pauleikhoff, Giovanni Staurenghi, Armin Wolf, Daniel Lorand, Andreas Clemens & Benjamin Gmeiner. (2023) Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study. British Journal of Ophthalmology 107:1, pages 96-101.
Crossref
Crossref
Nancy Wang, Adrian Hunt, Vuong Nguyen, Janika Shah, Samantha Fraser‐Bell, Ian McAllister, Daniel Barthelmes, Mark Gillies & David Squirrell. (2022) One‐year real‐world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion. Clinical & Experimental Ophthalmology 50:9, pages 1038-1046.
Crossref
Crossref
Andrew Lotery, Andreas Clemens, Raman Tuli, Xun Xu, Masahiko Shimura, Marco Nardi, Focke Ziemssen, Cornelia Dunger-Baldauf & Ramin Tadayoni. (2021) Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study. Eye 36:8, pages 1656-1661.
Crossref
Crossref
Mateusz Niedzwiecki, Adrian Hunt, Vuong Nguyen, Hemal Mehta, Catherine Creuzot‐Garcher, Pierre‐Henry Gabrielle, Martin Guillemin, Samantha Fraser‐Bell, Jennifer Arnold, Ian L. McAllister, Mark Gillies & Daniel Barthelmes. (2021) 12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry. Acta Ophthalmologica 100:4.
Crossref
Crossref
Shan Yin, Yanyan Cui, Wanzhen Jiao & Bojun Zhao. (2022) Potential Prognostic Indicators for Patients With Retinal Vein Occlusion. Frontiers in Medicine 9.
Crossref
Crossref
Christian Wolfram & Marc Schargus. (2021) Das Hamburger Register für intravitreale Injektionstherapien (QIVOM)The Hamburg register for intravitreal injection therapies (QIVOM). Der Ophthalmologe 119:3, pages 280-287.
Crossref
Crossref
Qi Zhang, Yinfen Hou, Xiao Cao, Rongrong Zhang, Yinping Liu, Chenghua Wei, Changfan Wu, Lixin Mei & Pengfei Zhang. (2021) Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept. BMC Ophthalmology 21:1.
Crossref
Crossref
Sanjeeb Bhandari, Manish Poudel, Indira Paudyal, Pratibha L. Joshi, Chunu Shrestha, Govinda Paudyal & Eli Pradhan. (2021) Treatment outcomes of retinal vein occlusion in clinical practice in Nepal. BMC Ophthalmology 21:1.
Crossref
Crossref
Raja Narayanan, Aditya Kelkar, Zahir Abbas, Neha Goel, Manoj Soman, Naveen Naik, Aditya Sudhalkar, Jaydeep Walinjkar, Utkarsh Shah & Nitin Maksane. (2021) Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab. BMC Ophthalmology 21:1.
Crossref
Crossref
Mineo Kondo, Hidetaka Noma, Masahiko Shimura, Masahiko Sugimoto, Yoshitsugu Matsui, Kumiko Kato, Yoshitsugu Saishin, Masahito Ohji, Hiroto Ishikawa, Fumi Gomi, Kensaku Iwata, Shigeo Yoshida, Sentaro Kusuhara, Hiromasa Hirai, Nahoko Ogata, Takao Hirano, Toshinori Murata, Kotaro Tsuboi, Motohiro Kamei, Takamasa Kinoshita, Soichiro Kuwayama, Yoshio Hirano, Manami Ohta, Kazuhiro Kimura, Kei Takayama, Masaru Takeuchi, Yoshihiro Takamura, Fumiki Okamoto, Yoshinori Mitamura, Hiroto Terasaki, Taiji Sakamoto & on behalf of Japan Clinical Retina Study (J-CREST) Group. (2021) Background Factors Affecting Visual Acuity at Initial Visit in Eyes with Central Retinal Vein Occlusion: Multicenter Study in Japan. Journal of Clinical Medicine 10:23, pages 5619.
Crossref
Crossref
Masahiko Shimura, Takuya Utsumi, Makoto Imazeki, Kanako Yasuda & Hidetaka Noma. (2021) Efficacy-Based Aflibercept Treatment Regimen for Central Retinal Vein Occlusion. Ophthalmology Retina 5:11, pages 1177-1179.
Crossref
Crossref
M. Routier, J.-B. Ducloyer, H. Masse, O. Lebreton, P. Fossum, M. Clement & M. Weber. (2021) Étude rétrospective de vraie vie de patients traités par injections intra-vitréennes de dexaméthasone ou d’anti-VEGF pour œdèmes maculaires diabétiques ou secondaires à une occlusion veineuse rétinienne : à propos de 98 yeux. Journal Français d'Ophtalmologie 44:8, pages 1148-1158.
Crossref
Crossref
Ian L McAllister, Lynne A Smithies, Fred K Chen, David A Mackey & Paul G Sanfilippo. (2021) Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy. BMJ Open Ophthalmology 6:1, pages e000728.
Crossref
Crossref